Your browser doesn't support javascript.
Efficacy of lopinavir–ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: a meta-analysis
Future virology ; 2022.
Article in English | EuropePMC | ID: covidwho-1678760
ABSTRACT

Aim:

To evaluate the efficacy and safety of lopinavirritonavir (LPV/r) therapy in treating hospitalized COVID-19 patients. Materials &

methods:

Data from randomized and observational studies were included in meta-analyses. Primary outcomes were length of stay, time for SARS-CoV-2 test conversion, mortality, incidence of mechanical ventilation, time to body temperature normalization and incidence of adverse events.

Results:

Twenty-four studies (n = 10,718) were included. LPV/r demonstrated no significant benefit over the control groups in all efficacy outcomes. The use of LPV/r was associated with a significant increase in the odds of adverse events.

Conclusion:

Given the lack of efficacy and increased incidence of adverse events, the clinical use of LPV/r in hospitalized COVID-19 patients is not recommended.
Search on Google
Collection: Databases of international organizations Database: EuropePMC Type of study: Observational study / Randomized controlled trials / Reviews Language: English Journal: Future virology Year: 2022 Document Type: Article
Search on Google
Collection: Databases of international organizations Database: EuropePMC Type of study: Observational study / Randomized controlled trials / Reviews Language: English Journal: Future virology Year: 2022 Document Type: Article